

Topical Option For Persistent Fungal Infections

Sertaconazole
Nitrate Cream 2%



Ertaczo[®] (sertaconazole nitrate) cream, 2% 60 g

NDC: 85437-004-60

INDICATIONS:

ERTACZO[®] cream, 2%, is indicated for the topical treatment of interdigital tinea pedis in immunocompetent adult and pediatric patients 12 years of age and older caused by *Trichophyton rubrum*, *Trichophyton mentagrophytes*, and *Epidermophyton floccosum*.

WARNINGS AND PRECAUTIONS:

Local Adverse Reactions

If irritation develops, discontinue treatment and institute appropriate therapy.

Physicians should exercise caution when prescribing ERTACZO cream, 2%, to patients known to be sensitive to azole antifungals since cross-reactivity may occur.

ADVERSE REACTIONS:

Most common adverse reactions observed in clinical trials (incidence >2%) were contact dermatitis, dry skin, burning skin, application site skin tenderness.

For full Prescribing Information,
see attached Product Insert.

You are encouraged to report negative side effects of
prescription drugs to the FDA. Visit fda.gov/medwatch
or call 1-800-FDA-1088.

Helps Patients Through Twice-Daily Dosing

Ertaczo is a treatment option for adults and children 12 years of age and older with interdigital tinea pedis.

Well-Tolerated
Topical Option

Broad-Spectrum
Antifungal Activity



COPAY INFORMATION

\$150 OFF PER TUBE*

BIN #: 610600

PCN #: AS

GROUP #: 349

ID #: 34905139472

Help Desk: 877-274-3244

*Terms and conditions may apply.

HOW TO WRITE:

Ertaczo

Apply to affected skin twice daily for 4 weeks.

2%

Dispense as written



Visit our website at:
FLEXDOSING.COM

©2026 Flexdosing.com
All rights reserved.
LB-FD-02 Rev. 05/2026

ERTACZO® - sertaconazole nitrate cream
Coral Way Pharma, LLC

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use ERTACZO® Cream safely and effectively. See full prescribing information for ERTACZO® Cream. ERTACZO® (sertaconazole nitrate) cream, for topical use
Initial U.S. Approval: 2003

INDICATIONS AND USAGE

ERTACZO® cream, 2% is an azole antifungal indicated for the topical treatment of interdigital tinea pedis in immunocompetent adult and pediatric patients 12 years of age and older caused by *Trichophyton rubrum*, *Trichophyton mentagrophytes*, and *Epidermophyton floccosum*. (1)

DOSAGE AND ADMINISTRATION

- Apply ERTACZO® cream, 2% to the affected and immediate surrounding area(s) twice daily for 4 weeks. (2)
- Not for ophthalmic, oral, or intravaginal use. (2)

DOSAGE FORMS AND STRENGTHS

Cream, 2%. (3)

CONTRAINDICATIONS

None. (4)

ADVERSE REACTIONS

Most common adverse reactions observed in clinical trials (incidence >2%) were contact dermatitis, dry skin, burning skin, application site skin tenderness. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Coral Way Pharma, LLC at 1-888-402-8874 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 4/2026

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Local Adverse Reactions

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

6.2 Postmarketing Experience

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

8.2 Lactation

8.4 Pediatric Use

8.5 Geriatric Use

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

12.2 Pharmacokinetics

12.3 Microbiology

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

ERTACZO® cream, 2%, is indicated for the topical treatment of interdigital tinea pedis in immunocompetent adult and pediatric patients 12 years of age and older caused by *Trichophyton rubrum*, *Trichophyton mentagrophytes*, and *Epidermophyton floccosum*.

2 DOSAGE AND ADMINISTRATION

- Apply ERTACZO® cream, 2% twice daily for 4 weeks. Apply a sufficient amount of ERTACZO® cream, 2% to cover both the affected areas between the toes and the immediately surrounding healthy skin.
- Use ERTACZO® cream, 2% for the full treatment time recommended by the physician, even though symptoms may have improved.
- Dry the affected area(s) thoroughly before application, if using ERTACZO® cream, 2% after bathing.
- Wash hands after use.
- Avoid the use of occlusive dressings or wrappings.
- For topical use.
- Not for ophthalmic, oral, or intravaginal use.

3 DOSAGE FORMS AND STRENGTHS

Cream, 2%. Each gram of ERTACZO® cream, 2%, contains 17.5 mg of sertaconazole (as sertaconazole nitrate, 20 mg) in a white cream base.

4 CONTRAINDICATIONS

None.

5 WARNINGS AND PRECAUTIONS

5.1 Local Adverse Reactions

If irritation develops, discontinue treatment and institute appropriate therapy. Sections or subsections omitted from the full prescribing information are not listed.

Physicians should exercise caution when prescribing ERTACZO® cream, 2%, to patients known to be sensitive to azole antifungals since cross-reactivity may occur.

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In clinical trials, cutaneous adverse events occurred in 7 of 297 (2%) subjects (2 of them severe) receiving ERTACZO[®] cream, 2%, and in 7 of 291 (2%) subjects (2 of them severe) receiving vehicle. These reported cutaneous adverse events included contact dermatitis, dry skin, burning skin, and application site skin tenderness.

In a dermal sensitization trial, 8 of 202 evaluable subjects tested with ERTACZO[®] cream, 2%, and 4 of 202 evaluable subjects tested with vehicle exhibited a erythematous reaction in the challenge phase. There was no evidence of cumulative irritation or contact sensitization in a repeated insult patch test involving 202 healthy volunteers.

6.2 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of ERTACZO[®] cream, 2%. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Cutaneous adverse events: erythema, pruritus, vesiculation, desquamation, and hyperpigmentation.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

There are no available data on ERTACZO[®] cream, 2% use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal reproduction studies, there were no adverse developmental effects observed with oral administration of sertaconazole nitrate to pregnant rats and rabbits during organogenesis at doses 40 and 80 times, respectively, the maximum recommended human dose (MRHD) based on body surface area (BSA) comparison. In rats, when maternal dosing was continued until weaning, a reduction in live birth indices and an increase in the number of still-born pups was observed at doses 20 and 40 times the MRHD based on BSA comparison (see Data).

The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of major birth defects, loss and other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Data

Animal Data

Animal embryofetal development studies have not been conducted with ERTACZO[®] cream, 2%. Embryofetal development studies performed in pregnant rats and rabbits administered oral doses of sertaconazole nitrate up to 160 mg/kg/day (40 times [rats] and 80 times [rabbits] the MRHD based on a BSA comparison) during the period of organogenesis revealed no malformations or embryofetal developmental toxicity. In a pre- and postnatal

development study, pregnant rats were administered oral doses of sertaconazole nitrate from pregnancy day 6 to lactation day 20. A reduction in live birth indices and an increase in the number of still-born pups were seen at doses 20 and 40 times the MRHD based on BSA comparison.

8.2 Lactation

Risk Summary

There are no data available on the presence of sertaconazole in human or animal milk, its effects on the breastfed infant, or its effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for ERTACZO[®] cream, 2% and any potential adverse effects on the breastfed infant from ERTACZO[®] cream, 2% or from the underlying maternal condition.

8.4 Pediatric Use

The safety and effectiveness of ERTACZO[®] cream, 2%, have not been established in pediatric patients younger than 12 years of age.


8.5 Geriatric Use

Clinical trials of ERTACZO[®] cream, 2%, did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

11 DESCRIPTION

ERTACZO[®] (sertaconazole nitrate) cream, 2%, is for topical application. It contains the azole antifungal, sertaconazole nitrate. Sertaconazole nitrate contains one asymmetric carbon atom and exists as a racemic mixture of equal amounts of R and S enantiomers.

Sertaconazole nitrate is designated chemically as (±)-1-[2,4-dichloro-β-[(7-chlorobenzo-[b]thien-3-yl)methoxy]phenethyl]imidazole nitrate. It has a molecular weight of 500.8. The molecular formula is C₂₀H₁₅Cl₃N₂O₅ • HNO₃, and the structural formula is as follows:



Sertaconazole nitrate is a white or almost white powder. It is practically insoluble in water, soluble in methanol, and sparingly soluble in alcohol and in methylene chloride. Each gram of ERTACZO[®] cream, 2%, contains 17.5 mg of sertaconazole (as sertaconazole nitrate, 20 mg) in a white cream base of ethylene glycol, glyceryl isostearate, glycolized saturated glycerides, light mineral

oil, methylparaben, polyethylene glycol palmitostearate, polyoxyethylened saturated glycerides, purified water, and sorbic acid.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Sertaconazole nitrate is an azole antifungal [see Clinical Pharmacology (12.4)] .

12.2 Pharmacokinetics

In a multiple-dose pharmacokinetic trial that included 5 male subjects with interdigital tinea pedis (range of diseased area, 42 - 140 cm² ; mean, 93 cm²), ERTACZO[®] cream, 2%, was topically applied every 12 hours for a total of 13 doses to the diseased skin (0.5 g sertoconazole nitrate per 100 cm²). Sertoconazole concentrations in plasma measured by serial blood sampling for 72 hours after the thirteenth dose were below the limit of quantitation (2.5 ng/mL) of the analytical method used.

12.3 Microbiology

Mechanism of Action

Sertoconazole, an azole antifungal agent, inhibits fungal cytochrome P-450-mediated 14 alpha-lanosterol demethylase enzyme. This enzyme functions to convert lanosterol to ergosterol. Ergosterol is a key component of fungal cell membranes and lack of this component leads to fungal cell injury by leakage of key constituents in the cytoplasm from the cell.

Activity In Vitro and in Clinical Infections

Sertoconazole nitrate has been shown to be active against isolates of the following microorganisms in clinical infections [see Indications and Usage (1)] :

- *Trichophyton rubrum*
- *Trichophyton mentagrophytes*
- *Epidermophyton floccosum*

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

In a 2-year rat dermal carcinogenicity study, topical administration of sertoconazole nitrate cream did not increase the number of neoplastic lesions compared to control animals, at sertoconazole nitrate doses of up to 800 mg/kg/day (200 times the MRHD based on a BSA comparison).

No clastogenic potential was observed in a mouse micronucleus test. Sertoconazole nitrate was nonclastogenic in the in vivo mouse sister chromatid exchange assay. There was no evidence that sertoconazole nitrate induced unscheduled DNA synthesis in primary rat hepatocyte cultures.

Rats treated orally with up to 160 mg/kg/day of sertoconazole nitrate (40 times the MRHD based on a BSA comparison), exhibited no toxicity or adverse effects on reproductive performance or fertility in male or female rats.

14 CLINICAL STUDIES

In two randomized, double-blind clinical trials, subjects 12 years and older with interdigital tinea pedis applied either ERTACZO[®] cream, 2%, or vehicle, twice daily for 4 weeks. Subjects with moccasin-type (plantar) tinea pedis and/or onychomycosis were excluded from the trial. Two weeks after completion of therapy (6 weeks after beginning therapy), subjects were evaluated for signs and symptoms related to interdigital tinea pedis.

Treatment outcomes are summarized in the table below.

Treatment Outcomes as Percent (%) of Total Subjects with Interdigital Tinea Pedis	Trial 1		Trial 2	
	Sertoconazole	Vehicle	Sertoconazole	Vehicle
	Complete Cure*(Primary Efficacy Variable)	13/99 (13.1%)	3/92 (3.3%)	28/103 (27.2%)
Effective Treatment**	32/99 (32.3%)	11/92 (12.0%)	52/103 (50.5%)	16/103 (15.5%)
Mycological Cure***	49/99 (49.5%)	18/92 (19.6%)	71/103 (68.9%)	20/103 (19.4%)

* Complete Cure – Patients who had complete clearing of signs and symptoms and Mycological Cure.

** Effective Treatment – Patients who had minimal residual signs and symptoms of interdigital tinea pedis and Mycological Cure.

*** Mycological Cure – Patients who had both negative microscopic KOH preparation and negative fungal culture.

In clinical trials, complete cure in ERTACZO[®] cream, 2%-treated subjects was achieved in 32 of 160 (20%) subjects with *Trichophyton rubrum*, in 7 of 28 (25%) subjects with *Trichophyton mentagrophytes*, and in 1 of 13 (15%) subjects with *Epidermophyton floccosum*.

16 HOW SUPPLIED/STORAGE AND HANDLING

ERTACZO[®] cream, 2%, is white in color and supplied in tubes in the following size:

60-gram tube

NDC 85437-004-60

Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F)

[see USP Controlled Room Temperature].

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information). Instruct the patient of the following:

Administration Instructions

- ERTACZO[®] cream, 2% is for topical use only.
- Avoid contact with the eyes, mouth, vagina, and other mucous membranes.
- Dry the affected area(s) thoroughly before application, if using ERTACZO[®] cream, 2% after bathing.
- Wash hands after use.
- Use the medication for the full treatment time recommended by the physician, even though symptoms may have improved.
- Avoid the use of occlusive dressings unless otherwise directed by the physician [see Dosage and Administration (2)] .

Local Adverse Reactions

- Inform the physician if the area of application shows signs of increased irritation, redness, itching, burning, blistering, swelling, or oozing [see Warnings and Precautions (5.1)].

Distributed by:

Lacer Pharma, LLC
Biloxi, MS 39532 USA

Manufactured by:

Coral Way Pharma, LLC
San Antonio, TX 78213 USA

ERTACZO is a trademark of Lacer Pharma, LLC
141329

This Patient Information has been approved by the U.S.
Food and Drug Administration.
Revised: 04/2024

**PACKAGE/LABEL PRINCIPAL DISPLAY PANEL – 60 g
Carton**

NDC 85437-004-60

ERTACZO®

(sertaconazole nitrate) cream, 2%

Rx only

**For Topical Use Only - Not for Ophthalmic, Oral, or
Intravaginal Use**

Net Wt. 60 g